# AIMBLE

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aimble

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.aimble.com
- Total disclosed funding: $0.3M
- Latest round: Seed (Jul 1, 2021)
- Investors on record: 3

## About

AIMBLE is an innovative company specializing in AI-driven drug discovery, utilizing advanced technologies for efficient and precise identification of novel drug candidates. Its solutions cater primarily to the pharmaceutical and biotechnology sectors.AIMBLE, founded in 2020, is based in Seoul, South Korea, and focuses on AI-driven drug discovery. The company has undergone no significant pivots in its business strategy since inception. AIMBLE has raised a total of KRW 400.000 mn across three deals, with the latest funding round being a Seed round on July 1, 2021, led by investor Schmidt. The CEO of AIMBLE is Hyunjin Kim, who is instrumental in driving the company's vision and operations.AIMBLE specializes in an AI-driven drug discovery platform known as AIMBLE CADD, which integrates advanced technologies such as molecular docking, artificial intelligence, quantum calculations, and molecular dynamics simulations. This platform enables the identification and design of novel drug candidates with a focus on efficiency and precision. Additionally, AIMBLE operates the AIMBLE Synthesis Lab, facilitating the rapid construction of chemical compounds specifically designed through its CADD platform, allowing for expedited in-vitro and in-vivo experiments. The company primarily serves pharmaceutical and biotechnology sectors globally, with a focus on regions involved in pharmaceutical innovation, including North America, Europe, and parts of Asia.AIMBLE generates revenue through a combination of B2B partnerships and direct service offerings. Clients, primarily from the pharmaceutical and biotech industries, collaborate with AIMBLE to leverage its CADD platform and synthesis services, involving contractual agreements for access to its technology. Revenue is structured around service fees for drug design projects and synthesis services, as well as potential licensing agreements for proprietary technologies developed through the AIMBLE platform. Specific pricing plans and agreements are tailored to individual client needs, aligning with the complexity and scope of services provided.Following the most recent Seed funding round on July 1, 2021, AIMBLE plans to leverage this investment to enhance its AI-driven drug discovery platform and expand its services. The company aims to develop new products that will streamline drug discovery processes and enter new markets, particularly targeting expansions in North America and Europe by the end of 2023. The funding will support these initiatives as AIMBLE seeks to enhance its technology and establish more partnerships in key regions.

## Funding rounds

- Seed, Jul 1, 2021 — Korea Tech Incubator for Startup, Schmidt
- Seed, Jun 24, 2021, $0.3M — Schmidt
- Seed, Dec 11, 2020 — New Paradigm Investment

## Investors

- New Paradigm Investment (https://capitalatlas.ai/funds/new-paradigm-investment) — Seed
- Schmidt (https://capitalatlas.ai/funds/schmidt) — Seed
- Korea Tech Incubator for Startup — Seed